The side and the location of the primary tumor does not affect the probability of lymph node invasion in patients with renal cell carcinoma.


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 11 08 2018
accepted: 20 11 2018
pubmed: 27 11 2018
medline: 20 2 2020
entrez: 27 11 2018
Statut: ppublish

Résumé

To evaluate the role of side and location of the primary renal cell carcinoma (RCC) on the risk of lymph node invasion (LNI) and/or nodal progression (NP) during follow-up. We evaluated 2485 patients with unilateral RCC, surgically treated in a single tertiary care referral center. Outcomes were LNI at surgery and/or NP during follow-up. We studied if RCC side (left vs. right) and location (upper vs. middle vs. hilar vs. lower area vs. more than one area) affected the probability of LNI and/or NP at follow-up. Overall, 43 and 15% of patients underwent lymph node dissection and had LNI at surgery, respectively. During follow-up, 2.2% of patients had NP. Higher rates of LNI and NP were observed for patients with primary tumor located in more than one anatomical kidney area relative to patients with tumor in a single area (upper 11% vs. middle 10% vs. hilar 0%, vs. lower 12% vs. more than one area 26%, p < 0.01). cM1, cN1, pT2/pT3/pT4 disease and Fuhrman grade 3/4 were independent predictors of the study outcome (all p ≤ 0.01). Neither the RCC side nor the location reached the independent predictor status (all p > 0.1). Patients with single-side and more than one anatomical kidney area affected by RCC have higher rate of LNI at surgery and/or NP at follow-up. Neither side nor location of primary RCC tumor is related to the risk of harboring LNI at surgery and/or developing NP at follow-up.

Identifiants

pubmed: 30474699
doi: 10.1007/s00345-018-2573-3
pii: 10.1007/s00345-018-2573-3
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1623-1629

Commentaires et corrections

Type : CommentIn

Références

Kates M, Lavery HJ, Brajtbord J et al (2012) Decreasing rates of lymph node dissection during radical nephrectomy for renal cell carcinoma. Ann Surg Oncol 19:2693–2699. https://doi.org/10.1245/s10434-012-2330-6
doi: 10.1245/s10434-012-2330-6 pubmed: 22526899
Capitanio U, Leibovich BC (2017) The rationale and the role of lymph node dissection in renal cell carcinoma. World J Urol 35:497–506. https://doi.org/10.1007/s00345-016-1886-3
doi: 10.1007/s00345-016-1886-3 pubmed: 27364520
Ravaud A, Motzer RJ, Pandha HS et al (2016) Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med 375:2246–2254. https://doi.org/10.1056/NEJMoa1611406
doi: 10.1056/NEJMoa1611406 pubmed: 27718781
Capitanio U, Montorsi F (2016) Renal cancer. Lancet 387:894–906. https://doi.org/10.1016/S0140-6736(15)00046-X
doi: 10.1016/S0140-6736(15)00046-X pubmed: 26318520
Bex A (2016) Follow-up for renal cell carcinoma: absence of evidence and beyond. Eur Urol Focus 1:282–283. https://doi.org/10.1016/j.euf.2015.07.006
doi: 10.1016/j.euf.2015.07.006 pubmed: 28723400
Karmali RJ, Suami H, Wood CG, Karam JA (2014) Lymphatic drainage in renal cell carcinoma: back to the basics. BJU Int 114:806–817. https://doi.org/10.1111/bju.12814
doi: 10.1111/bju.12814 pubmed: 24841690
Bex A, Vermeeren L, Meinhardt W et al (2011) Intraoperative sentinel node identification and sampling in clinically node-negative renal cell carcinoma: initial experience in 20 patients. World J Urol 29:793–799. https://doi.org/10.1007/s00345-010-0615-6
doi: 10.1007/s00345-010-0615-6 pubmed: 21107845
Sherif AM, Eriksson E, Thörn M et al (2012) Sentinel node detection in renal cell carcinoma. A feasibility study for detection of tumour-draining lymph nodes. BJU Int 109:1134–1139. https://doi.org/10.1111/j.1464-410X.2011.10444.x
doi: 10.1111/j.1464-410X.2011.10444.x pubmed: 21883833
Kuusk T, De Bruijn R, Brouwer RO et al (2017) Lymphatic drainage from renal tumors in vivo: a prospective sentinel node study using SPECT/CT imaging. J Urol. https://doi.org/10.1016/j.juro.2017.11.112
doi: 10.1016/j.juro.2017.11.112
Paner GP, Stadler WM, Hansel DE et al (2018) Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers. Eur Urol. https://doi.org/10.1016/j.eururo.2017.12.018
doi: 10.1016/j.eururo.2017.12.018
Delahunt B, Cheville JC, Martignoni G et al (2013) The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol:1490–1504
Blute ML, Leibovich BC, Cheville JC et al (2004) A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. J Urol 172:465–469. https://doi.org/10.1097/01.ju.0000129815.91927.85
doi: 10.1097/01.ju.0000129815.91927.85 pubmed: 15247704 pmcid: 15247704
Capitanio U, Jeldres C, Patard J-J et al (2009) Stage-specific effect of nodal metastases on survival in patients with non-metastatic renal cell carcinoma. BJU Int 103:33–37. https://doi.org/10.1111/j.1464-410X.2008.08014.x
doi: 10.1111/j.1464-410X.2008.08014.x pubmed: 18990161 pmcid: 18990161
Lughezzani G, Capitanio U, Jeldres C et al (2009) Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: a population-based perspective. Cancer 115:5680–5687. https://doi.org/10.1002/cncr.24682
doi: 10.1002/cncr.24682 pubmed: 19824083 pmcid: 19824083
Blom JHM, Van Poppel H, Maréchal JM et al (2009) Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 55:28–34. https://doi.org/10.1016/j.eururo.2008.09.052
doi: 10.1016/j.eururo.2008.09.052 pubmed: 18848382
Dell’Oglio P, Larcher A, Muttin F et al (2017) Lymph node dissection should not be dismissed in case of localized renal cell carcinoma in the presence of larger diseases. Urol Oncol 35:662.e9–662.e15. https://doi.org/10.1016/j.urolonc.2017.07.010
doi: 10.1016/j.urolonc.2017.07.010
Bekema HJ, MacLennan S, Imamura M et al (2013) Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma. Eur Urol 64:799–810. https://doi.org/10.1016/j.eururo.2013.04.033
doi: 10.1016/j.eururo.2013.04.033 pubmed: 23643550
Bhindi B, Wallis CJD, Boorjian SA et al (2018) The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis. BJU Int. https://doi.org/10.1111/bju.14127
doi: 10.1111/bju.14127
Delamere G, Poirier P, Cunéo B (1904) The lymphatics. Ann Surg 39:1040–1044. https://doi.org/10.1097/00000658-190406000-00014
doi: 10.1097/00000658-190406000-00014
Clodius L (2006) M. Földi, E. Földi, S. Kubik (eds) Textbook of lymphology (in German), 6th edn. Elsevier, Munich, 2005. ISBN 3-437-45322-X, US\$ 95.00. Eur J Plastic Surg 28:537–538. https://doi.org/10.1007/s00238-005-0024-z
doi: 10.1007/s00238-005-0024-z
Brouwer OR, Noe A, Olmos RAV, Bex A (2013) Lymphatic drainage from renal cell carcinoma along the thoracic duct visualized with SPECT/CT. Lymphat Res Biol 11:233–238. https://doi.org/10.1089/lrb.2013.0017
doi: 10.1089/lrb.2013.0017 pubmed: 24364847
Hultén L, Rosencrantz M, Seeman T et al (1969) Occurrence and localization of lymph node metastases in renal carcinoma. A lymphographic and histopathological investigation in connection with nephrectomy. Scand J Urol Nephrol 3:129–133
doi: 10.3109/00365596909135393
Johnsen JA, Hellsten S (1997) Lymphatogenous spread of renal cell carcinoma: an autopsy study. J Urol 157:450–453
doi: 10.1016/S0022-5347(01)65167-X

Auteurs

Alessandro Nini (A)

Unit of Urology, University Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.
Renal Cancer Unit, Division of Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.

Alessandro Larcher (A)

Unit of Urology, University Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.
Renal Cancer Unit, Division of Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.

Walter Cazzaniga (W)

Unit of Urology, University Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.
Renal Cancer Unit, Division of Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.

Paolo Dell'Oglio (P)

Unit of Urology, University Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.
Renal Cancer Unit, Division of Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.

Francesco Cianflone (F)

Unit of Urology, University Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.
Renal Cancer Unit, Division of Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.

Fabio Muttin (F)

Unit of Urology, University Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.
Renal Cancer Unit, Division of Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.

Francesco Ripa (F)

Unit of Urology, University Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.
Renal Cancer Unit, Division of Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.

Andrea Salonia (A)

Unit of Urology, University Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.
Renal Cancer Unit, Division of Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.

Alberto Briganti (A)

Unit of Urology, University Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.
Renal Cancer Unit, Division of Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.

Francesco Montorsi (F)

Unit of Urology, University Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.
Renal Cancer Unit, Division of Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.

Roberto Bertini (R)

Unit of Urology, University Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.
Renal Cancer Unit, Division of Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.

Umberto Capitanio (U)

Unit of Urology, University Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy. umbertocapitanio@gmail.com.
Renal Cancer Unit, Division of Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy. umbertocapitanio@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH